Detail page

Knowledge Web

Person

Markus Möhler

Arzt

Name	Markus Möhler
Place	Deutschland
Gender	männlich
Academic degree	Prof. Dr. med.
Profession	Arzt (characteristic profession)
Variant	Markus Moehler M. Möhler
Further information	Leiter der gastroenterologisch-onkologischen Ambulanz der I. Medizinischen Klinik und Poliklinik der Universitätsmedizin Mainz (Johannes Gutenberg Universität)
Record type	Person
GND-Identifier	112161955X
Record ID	112161955X
Involved in show all Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction Zolbetuximab (Vyloy TM) : Erste Claudin 18.2-gerichtete Antikörpertherapie in Kombination mit Chemotherapie bei lokal fortgeschrittenem inoperablem oder metastasiertem HER2-negativem Adenokarzinom des Magens oder des gastroösophagealen Übergangs Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415) Chemoradiotherapy in geriatric patients with squamous cell carcinoma of the esophagus: multi-center analysis on the value of standard treatment in the elderly Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306 Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer – Data From a Randomized German Phase II Trial Regorafenib und Nivolumab (RegoNivo) versus Drittlinie bei Therapie-resistenten Ösophagus-Magen-Karzinomen (GEJC) : INTEGRATE IIb, eine internationale randomisierte Phase-III-Studie für GEJC-Patienten, AIO-STO-0221/ass Studien der Arbeitsgruppe Magen-Ösophagus-Tumoren der Arbeitsgemeinschaft Internistische Onkologie (AIO) Morbidity and mortality of neutropenic patients in visceral surgery: a narrative review Survival after secondary liver resection in metastatic colorectal cancer : comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3) Comparative analysis of nuclear and mitochondrial DNA from tissue and liquid biopsies of colorectal cancer patients Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first‐line treatment within the randomized Phase III trial FIRE‐3 (AIO KRK‐0306) The role of p53 dysfunction in colorectal cancer and its implication for therapy FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2) RAMIRIS : Wirksamkeit von Ramucirumab plus FOLFIRI vs. Ramucirumab plus Paclitaxel bei Patienten mit fortgeschrittenem oder metastasiertem Adenokarzinom des Magens oder des gastroösophagealen Übergangs, die auf eine Erstlinientherapie progredient sind – eine randomisierte Phase-II/III-Studie der AIO Young-onset gastric cancer and Epstein–Barr Virus (EBV) – a major player in the pathogenesis? Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper Dihydropyrimidine dehydrogenase testing prior to treatment with 5-Fluorouracil, Capecitabine, and Tegafur : a consensus paper Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2) Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL Immunotherapy : new options in gastrointestinal cancers? Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071) ASCO- und ESMO-Update 2017 – Neuigkeiten vom 53. Meeting der American Society of Clinical Oncology/ASCO 2017 und European Society for Medical Oncology/ESMO-Congress 2017 Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis HER2 testing in gastric cancer: results of a German expert meeting Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program Diagnostik und medikamentöse Therapie des Magenkarzinoms Diagnostik und medikamentöse Therapie des Magenkarzinoms Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus : a randomized, placebo-controlled phase II AIO trial with serum biomarker program Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?! International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer : results of the FOGT-4 trial Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction Efficacy and Safety of Irinotecan-Based Chemotherapy for Advanced Colorectal Cancer outside Clinical Trials: An Observational Study Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases-a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study) Efficacy and Safety of Irinotecan-Based Chemotherapy for Advanced Colorectal Cancer outside Clinical Trials: An Observational Study HER2-Diagnostik und zielgerichtete Therapie beim fortgeschrittenen Magenkarzinom Palliative Therapie des kolorektalen Karzinoms Diagnostik und Therapie von Lebermetastasen bei kolorektalem Primärtumor Therapie primär nichtresektabler Lebermetastasen Operative und perioperative Therapie von Lebermetastasen Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer Neue Therapieoptionen für Patienten mit gastrointestinalen Karzinomen : neue Zytostatika und onkolytische Therapie mit Parvovirus H1 Charakterisierung der Hemmung der HSV-induzierten SV40-DNA-Amplifikation durch das rep-Gen vom Adeno-assoziierten Virus

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Markus Möhler

Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction

Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction

Zolbetuximab (Vyloy TM) : Erste Claudin 18.2-gerichtete Antikörpertherapie in Kombination mit Chemotherapie bei lokal fortgeschrittenem inoperablem oder metastasiertem HER2-negativem Adenokarzinom des Magens oder des gastroösophagealen Übergangs

Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract

German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer

Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)

Chemoradiotherapy in geriatric patients with squamous cell carcinoma of the esophagus: multi-center analysis on the value of standard treatment in the elderly

Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306

Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer – Data From a Randomized German Phase II Trial

Regorafenib und Nivolumab (RegoNivo) versus Drittlinie bei Therapie-resistenten Ösophagus-Magen-Karzinomen (GEJC) : INTEGRATE IIb, eine internationale randomisierte Phase-III-Studie für GEJC-Patienten, AIO-STO-0221/ass

Studien der Arbeitsgruppe Magen-Ösophagus-Tumoren der Arbeitsgemeinschaft Internistische Onkologie (AIO)

Morbidity and mortality of neutropenic patients in visceral surgery: a narrative review

Survival after secondary liver resection in metastatic colorectal cancer : comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3)

Comparative analysis of nuclear and mitochondrial DNA from tissue and liquid biopsies of colorectal cancer patients

Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first‐line treatment within the randomized Phase III trial FIRE‐3 (AIO KRK‐0306)

The role of p53 dysfunction in colorectal cancer and its implication for therapy

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)

Young-onset gastric cancer and Epstein–Barr Virus (EBV) – a major player in the pathogenesis?

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper

Dihydropyrimidine dehydrogenase testing prior to treatment with 5-Fluorouracil, Capecitabine, and Tegafur : a consensus paper

Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL

Immunotherapy : new options in gastrointestinal cancers?

Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)

ASCO- und ESMO-Update 2017 – Neuigkeiten vom 53. Meeting der American Society of Clinical Oncology/ASCO 2017 und European Society for Medical Oncology/ESMO-Congress 2017

Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies

Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis

HER2 testing in gastric cancer: results of a German expert meeting

Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Diagnostik und medikamentöse Therapie des Magenkarzinoms

Diagnostik und medikamentöse Therapie des Magenkarzinoms

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus : a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial

Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!

International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer : results of the FOGT-4 trial

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

Efficacy and Safety of Irinotecan-Based Chemotherapy for Advanced Colorectal Cancer outside Clinical Trials: An Observational Study

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases-a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)

Efficacy and Safety of Irinotecan-Based Chemotherapy for Advanced Colorectal Cancer outside Clinical Trials: An Observational Study

HER2-Diagnostik und zielgerichtete Therapie beim fortgeschrittenen Magenkarzinom

Palliative Therapie des kolorektalen Karzinoms

Diagnostik und Therapie von Lebermetastasen bei kolorektalem Primärtumor

Therapie primär nichtresektabler Lebermetastasen

Operative und perioperative Therapie von Lebermetastasen

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer

Neue Therapieoptionen für Patienten mit gastrointestinalen Karzinomen : neue Zytostatika und onkolytische Therapie mit Parvovirus H1

Charakterisierung der Hemmung der HSV-induzierten SV40-DNA-Amplifikation durch das rep-Gen vom Adeno-assoziierten Virus